MedTrace Logo

Genetic Risk Stratification for Primary Prevention of CAD in Men and Pre & Post-menopausal Women

NCT05169840 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2023-11-24

No results posted yet for this study

Summary

The investigators propose to genotype males and females at age 40 years and older, who are asymptomatic and without known heart disease (N=2000). DNA from a blood sample will be genotyped for millions of genetic risk variants for CAD by Baylor College of Medicine Human Genome Sequencing Center Clinical Laboratory (HGSC-CL) in a CLIA-approved laboratory.

The overall objective after 2 years is to determine if genetic screening for risk of CAD in asymptomatic men and women has the discriminatory power to detect those at highest risk who would potentially benefit most from appropriate primary prevention. It will also determine whether the GRS is appropriate for different ethnic and race groups such as Hispanics, African Americans and Whites, and to what extent those individuals knowing that they are at higher risk, are more likely to seek further advice on management of the risks (either through changes in lifestyle or therapy).

Conditions

Interventions

OTHER

Genetic Risk Score for Coronary Artery Disease

Blood samples will be genotyped for million of genetic risk variants for Coronary Artery Disease (CAD)

Sponsors & Collaborators

  • Chandler Regional Medical Center

    collaborator UNKNOWN

  • Mercy Gilbert Medical Center

    collaborator UNKNOWN

  • St. Joseph's Hospital and Medical Center, Phoenix

    lead OTHER

Principal Investigators

  • Robert Roberts, MD · Dignity Health

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-23
Primary Completion
2024-06-15
Completion
2024-06-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05169840 on ClinicalTrials.gov